Get the Stockscreener App
118.51
4.93%
5.57
Pre-market:
118.70
0.19
+0.16%
Corcept Therapeutics Inc stock is traded at $118.51, with a volume of 847.70K.
It is up +4.93% in the last 24 hours and down -3.84% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
See More
Previous Close:
$112.94
Open:
$111.86
24h Volume:
847.70K
Relative Volume:
0.66
Market Cap:
$12.81B
Revenue:
$769.10M
Net Income/Loss:
$46.67M
P/E Ratio:
338.60
EPS:
0.35
Net Cash Flow:
$119.79M
1W Performance:
+3.18%
1M Performance:
-3.84%
6M Performance:
+250.41%
1Y Performance:
+41.35%
1-Day Range:
$111.68
$119.15
1-Week Range:
$108.41
$119.15
52-Week Range:
$28.66
$126.38
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
118.51 | 12.81B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-26 | Upgrade | UBS | Neutral → Buy |
| Mar-26-26 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Corcept Therapeutics Announces New Endocrinology Division President - The Globe and Mail
The Escalator: Bavarian Nordic, Acumetis, Corcept and more - mmm-online.com
CORT Looks 59.9% Overvalued on GF Value™ - GuruFocus
Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires - citybiz
Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant - TradingView
Corcept names Justin Gunn to lead endocrinology division By Investing.com - Investing.com Canada
Corcept Announces Planned Leadership Transition - finance.yahoo.com
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus - Yahoo Finance
Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle - finance.yahoo.com
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer - Your Wyoming Link
Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to S&P 400 Health Care - marketscreener.com
Corcept Therapeutics shares surge 22% after Q2 beat, guidance raise - scanx.trade
Corcept Therapeutics president Vieira sells $29,842 of stock By Investing.com - Investing.com South Africa
Corcept Therapeutics president Vieira sells $29,842 of stock - Investing.com
Corcept Therapeutics (CORT) oncology president sells shares under 10b5-1 plan - Stock Titan
Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week - Seeking Alpha
Corcept Therapeutics Incorporated Receives CHMP Recommendation For EU Marketing Authorization For Lifyorli (Relacorilant) Combined With Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer - marketscreener.com
CORT Looks 57.2% Overvalued on GF Value™ Amid EMA Relacorilant N - GuruFocus
Corcept Says EU Panel Backs Ovarian Cancer Drug Combination for Approval - marketscreener.com
Corcept’s relacorilant receives EU panel backing for ovarian cancer By Investing.com - Investing.com Canada
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant) - finance.yahoo.com
Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Combines Strong Growth With a Constructive Technical Setup - ChartMill
Corcept (CORT) director offloads 10,000 shares under preset plan - Stock Titan
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? - Eastern Progress
Corcept Grows to Mid-Cap on Institutional Support - FXEmpire
Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common Stocks - Moomoo
Corcept Therapeutics (CORT) director plans $3.34M stock sale - Stock Titan
Stock option exercise to drive 10,000-share sale at Corcept (NASDAQ: CORT) - Stock Titan
Corcept Therapeutics (CORT) Short Interest & Short Float | Updated Sep 2026 $CORT - MarketBeat
Corcept Therapeutics posts strong Q2 revenue, e... - Pluang
Corcept president Sean Maduck sells $2.86m in stock By Investing.com - Investing.com South Africa
Corcept Therapeutics Insider Sold Shares Worth $2,860,737, According to a Recent SEC Filing - marketscreener.com
Corcept Therapeutics Insider Sold Shares Worth $6,460,766, According to a Recent SEC Filing - marketscreener.com
Corcept president Sean Maduck sells $2.86m in stock - Investing.com
Corcept Therapeutics oncology president sells $6.46m in shares By Investing.com - Investing.com Australia
Corcept Therapeutics oncology president sells $6.46m in shares - investing.com
Corcept Therapeutics (CORT) CFO adds shares via plan and restricted awards - Stock Titan
Corcept (CORT) oncology president reports shares and 480K options - stocktitan.net
CORCEPT Therapeutics Officer Vieira Roberto Wandenkolk to Sell 75,295 Shares Including 74,999 Stock Options (NASDAQ: CORT) - Kalkine Media
$8.3M stock sale planned at Corcept (NASDAQ: CORT) - Stock Titan
QQQ Stock Price TodayGet QQQ News, Analysis and Trading Ideas - Stocktwits
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report? - finance.yahoo.com
Corcept Therapeutics' Sean Maduck Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - Kalkine Media
Corcept (NASDAQ: CORT) director to sell 26,685 shares - Stock Titan
$22M stock sale lined up at Corcept Therapeutics (NASDAQ: CORT) - Stock Titan
Corcept Therapeutics Stock 6-Day Winning Spree: Stock Climbs 11% - Trefis
Corcept Therapeutics stock hits all-time high at 122.5 USD By Investing.com - Investing.com Canada
Corcept Therapeutics(CORT.US) Director Sells US$12.25 Million in Common Stock - Moomoo
Corcept Therapeutics rated Strong Buy with 44% revenue growth and key FDA decisions ahead - Pluang
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):